Ademi LLP is investigating PRA Health (NASDAQ: PRAH) for possible breaches of fiduciary duty and other violations of law in its transaction with Icon.
Ademi LLP alleges PRA Health’s financial outlook is excellent and yet PRA Health shareholders will receive only $80 in cash and 0.4125 shares of Icon stock for each PRA Health share. The merger agreement unreasonably limits competing bids for PRA Health by prohibiting solicitation of further bids, and imposing a termination penalty if PRA Health accepts a superior bid. PRA Health insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of PRA Health’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for PRA Health.